{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:46:59Z","timestamp":1786985219433,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009045","name":"Jagiellonian University Medical College in Krak\u00f3w","doi-asserted-by":"publisher","award":["N42\/DBS\/000039"],"award-info":[{"award-number":["N42\/DBS\/000039"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009045","name":"Jagiellonian University Medical College in Krak\u00f3w","doi-asserted-by":"publisher","award":["N42\/DBS\/000041"],"award-info":[{"award-number":["N42\/DBS\/000041"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bioorg.2020.104033","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T21:41:23Z","timestamp":1592516483000},"page":"104033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["8-Benzylaminoxanthine scaffold variations for selective ligands acting on adenosine A2A receptors. Design, synthesis and biological evaluation"],"prefix":"10.1016","volume":"101","author":[{"given":"Micha\u0142","family":"Za\u0142uski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Schabikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ja\u015bko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bry\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Olejarz-Maciej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"G\u0142uch-Lutwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Zygmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Kuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gniewomir","family":"Latacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Vielmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa E.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kie\u0107-Kononowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.104033_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcin.2014.02.009","article-title":"Adenosine: physiology, pharmacology, and clinical applications","volume":"7","author":"Layland","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.bioorg.2020.104033_b0010","doi-asserted-by":"crossref","unstructured":"B.B. Fredholm, I.J. AP, K.A. Jacobson, K.N. Klotz, J. Linden, International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors, Pharmacol Rev. 53 (2001) 527\u2013552.","DOI":"10.1016\/S0031-6997(24)01511-4"},{"key":"10.1016\/j.bioorg.2020.104033_b0015","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.yexcr.2010.02.004","article-title":"Adenosine receptors as drug targets","volume":"316","author":"Fredholm","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bioorg.2020.104033_b0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets \u2014 what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2020.104033_b0025","doi-asserted-by":"crossref","unstructured":"G. Burnstock, A. Verkhratsky, Receptors for Purines and Pyrimidines, in: Purinergic Signal. Nerv. Syst., 2012: pp. 119\u2013244. https:\/\/doi.org\/10.1007\/978-3-642-28863-0_5.","DOI":"10.1007\/978-3-642-28863-0_5"},{"key":"10.1016\/j.bioorg.2020.104033_b0030","doi-asserted-by":"crossref","unstructured":"C.E. M\u00fcller, J. Maurinsh, R. Sauer, Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors., Eur. J. Pharm. Sci. 10 (2000) 259\u201365. https:\/\/doi.org\/S0928098700000646 [pii].","DOI":"10.1016\/S0928-0987(00)00064-6"},{"key":"10.1016\/j.bioorg.2020.104033_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2020.104033_b0040","first-page":"1","article-title":"Inhibition of A2A adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455","volume":"7","author":"Hatok","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2020.104033_b0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bcp.2018.08.011","article-title":"Adenosine activates G \u03b1 s proteins and inhibits C3a-induced activation of human mast cells","volume":"156","author":"Arizmendi","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2020.104033_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.91954","article-title":"Induction of antiinflammatory purinergic signaling in activated human iNKT cells","volume":"3","author":"Yu","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.bioorg.2020.104033_b0055","article-title":"Adenosine Receptors in Health and Disease, Springer, Berlin Heidelberg, Berlin","author":"Wilson","year":"2009","journal-title":"Heidelberg"},{"key":"10.1016\/j.bioorg.2020.104033_b0060","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2326-6066.CIR-18-0056","article-title":"A2AR antagonism with CPI-444 induces Antitumor responses and augments efficacy to anti\u2013PD-(L)1 and anti\u2013CTLA-4 in preclinical models","volume":"6","author":"Willingham","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bioorg.2020.104033_b0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14737140.2017.1316197","article-title":"Expert review of anticancer therapy targeting adenosine in cancer immunotherapy : a review of recent progress targeting adenosine in cancer immunotherapy : a review of recent progress","volume":"17","author":"Whiteside","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2020.104033_b0070","first-page":"1","article-title":"Expert opinion on drug discovery targeting adenosine A 2A receptor antagonism for treatment of cancer","volume":"00","author":"Congreve","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2020.104033_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13321-017-0249-4","article-title":"Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases","volume":"9","author":"Kalash","year":"2017","journal-title":"J. Cheminform."},{"key":"10.1016\/j.bioorg.2020.104033_b0080","article-title":"Methylxanthines, Springer, Berlin Heidelberg, Berlin","author":"Fredholm","year":"2011","journal-title":"Heidelberg"},{"key":"10.1016\/j.bioorg.2020.104033_b0085","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1755-5949.2009.00126.x","article-title":"Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Fuxe","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bioorg.2020.104033_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules22040676","article-title":"Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration","volume":"22","author":"Stockwell","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2020.104033_b0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/cn2000537","article-title":"Adenosine A 2A receptor antagonists and parkinson\u2019s disease","volume":"2","author":"Shook","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2020.104033_b0100","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.neurobiolaging.2014.03.027","article-title":"Beneficial effects of caffeine in a transgenic model of Alzheimer\u2019s disease-like tau pathology","volume":"35","author":"Laurent","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bioorg.2020.104033_b0105","doi-asserted-by":"crossref","unstructured":"D.A. Hussar, New Drugs 2020, part 1, Nursing (Lond). (2019) 1. https:\/\/doi.org\/10.1097\/01.NURSE.0000651608.77613.29.","DOI":"10.1097\/01.NURSE.0000651608.77613.29"},{"key":"10.1016\/j.bioorg.2020.104033_b0110","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/14656566.2018.1524876","article-title":"Istradefylline for the treatment of Parkinson\u2019s disease: is it a promising strategy?","volume":"19","author":"Torti","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2020.104033_b0115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ana.21313","article-title":"Adenosine A 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms","volume":"63","author":"Yu","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bioorg.2020.104033_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-4-47","article-title":"Does neuroinflammation fan the flame in neurodegenerative diseases?","volume":"4","author":"Frank-Cannon","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bioorg.2020.104033_b0125","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11910-012-0283-6","article-title":"Neuroinflammation and non-motor symptoms: The dark passenger of parkinson\u2019s disease?","volume":"12","author":"Barnum","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.bioorg.2020.104033_b0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1476-069X-13-80","article-title":"Particulate matter and risk of parkinson disease in a large prospective study of women","volume":"13","author":"Palacios","year":"2014","journal-title":"Environ. Heal."},{"key":"10.1016\/j.bioorg.2020.104033_b0135","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbrc.2015.03.109","article-title":"Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson\u2019s disease rat model","volume":"460","author":"Tian","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2020.104033_b0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12974-015-0320-x","article-title":"Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson\u2019s disease","volume":"12","author":"Valera","year":"2015","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.bioorg.2020.104033_b0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nbd.2014.03.004","article-title":"Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson\u2019s disease","volume":"67","author":"Gyoneva","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2020.104033_b0150","doi-asserted-by":"crossref","unstructured":"S.-P. Fu, J.-F. Wang, W.-J. Xue, H.-M. Liu, B. Liu, Y.-L. Zeng, S.-N. Li, B.-X. Huang, Q.-K. Lv, W. Wang, J.-X. Liu, Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson\u2019s disease models are mediated by GPR109A-dependent mechanisms, J. Neuroinflammation. 12 (2015) 9. https:\/\/doi.org\/10.1186\/s12974-014-0230-3.","DOI":"10.1186\/s12974-014-0230-3"},{"key":"10.1016\/j.bioorg.2020.104033_b0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuint.2013.01.029","article-title":"Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol","volume":"62","author":"Khan","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bioorg.2020.104033_b0160","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-020-02154-6","article-title":"Microglia and Parkinson\u2019s disease: footprints to pathology","author":"Lazdon","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bioorg.2020.104033_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/4807179","article-title":"Chronic systemic inflammation exacerbates neurotoxicity in a parkinson\u2019s disease model","volume":"2020","author":"Ugalde-Mu\u00f1iz","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2020.104033_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00104","article-title":"Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration","volume":"7","author":"Figueiredo-Pereira","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bioorg.2020.104033_b0175","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","article-title":"Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis","volume":"74","author":"Gagne","year":"2010","journal-title":"Neurology."},{"key":"10.1016\/j.bioorg.2020.104033_b0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/nmt-2016-0005","article-title":"Nondopaminergic treatments for Parkinson\u2019s disease: current and future prospects","volume":"6","author":"Freitas","year":"2016","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.bioorg.2020.104033_b0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","article-title":"Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson\u2019s Disease: A meta-analysis","volume":"324","author":"Chen","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bioorg.2020.104033_b0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"Ekavali, A review on Alzheimer\u2019s disease pathophysiology and its management: An update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Reports."},{"key":"10.1016\/j.bioorg.2020.104033_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2014.01.083","article-title":"Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review","volume":"101","author":"Rivera-Oliver","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2020.104033_b0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of alzheimer\u2019s disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2020.104033_b0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pbb.2015.02.020","article-title":"Anti-inflammatory, antioxidant, and antiparkinsonian effects of adenosine A2A receptor antagonists","volume":"132","author":"Zygmunt","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bioorg.2020.104033_b0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0304-3940(02)00524-4","article-title":"Effects of A1 and A2A adenosine receptor ligands in mouse acute models of pain","volume":"328","author":"Bastia","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bioorg.2020.104033_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01200","article-title":"PBF509, an adenosine A2A receptor antagonist with efficacy in rodent models of movement disorders","volume":"9","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2020.104033_b0220","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1016\/j.bmc.2016.09.003","article-title":"8-Substituted 1,3-dimethyltetrahydropyrazino[2,1- f ]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors","volume":"24","author":"Brunschweiger","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0225","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"Muller","year":"2011","journal-title":"BBA"},{"key":"10.1016\/j.bioorg.2020.104033_b0230","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1021\/acs.jmedchem.9b00071","article-title":"A2B adenosine receptor antagonists with picomolar potency","volume":"62","author":"Jiang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0235","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1016\/j.bmc.2007.04.018","article-title":"N9-Benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: Synthesis and structure-activity relationships at adenosine A1 and A2A receptors","volume":"15","author":"Drabczy\u0144ska","year":"2007","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0240","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/j.bmc.2016.07.028","article-title":"Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors","volume":"24","author":"Szyma\u0144ska","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0245","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/BF00717744","article-title":"2-Chloro-N6-[3H]cyclopentyladenosine ([3HCCPA) - a high affinity agonist radioligand for A1 adenosine receptors","volume":"340","author":"Klotz","year":"1989","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bioorg.2020.104033_b0250","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1021\/jm900413e","article-title":"1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A 2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity","volume":"52","author":"Borrmann","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0960-894X(01)00785-5","article-title":"[3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo [2,1\u2013i]-purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors","volume":"12","author":"M\u00fcller","year":"2002","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104033_b0260","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2019.02.004","article-title":"Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies","volume":"27","author":"Za\u0142uski","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0265","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.str.2011.06.014","article-title":"Structure of the adenosine A2A receptor in complex with ZM241385 and the Xanthines XAC and Caffeine","volume":"19","author":"Dor\u00e9","year":"2011","journal-title":"Structure."},{"key":"10.1016\/j.bioorg.2020.104033_b0270","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejmech.2018.09.021","article-title":"Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4\/7 inhibitors: a new approach for the treatment of pain","volume":"158","author":"Ch\u0142o\u0144-Rzepa","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0275","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1021\/jo0358574","article-title":"Multigram-scale syntheses, stability, and photoreactions of A 2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for parkinson\u2019s disease","volume":"69","author":"Hockemeyer","year":"2004","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11302-013-9358-3","article-title":"Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones","volume":"9","author":"Drabczy\u0144ska","year":"2013","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bioorg.2020.104033_b0285","doi-asserted-by":"crossref","unstructured":"A. Bilkei-Gorzo, O.M. Abo-Salem, A.M. Hayallah, K. Michel, C.E. M\u00fcller, A. Zimmer, Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia, Naunyn. Schmiedebergs. Arch. Pharmacol. 377 (2008) 65\u201376. https:\/\/doi.org\/10.1007\/s00210-007-0252-9.","DOI":"10.1007\/s00210-007-0252-9"},{"key":"10.1016\/j.bioorg.2020.104033_b0290","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/jpet.103.056036","article-title":"Antinociceptive effects of novel A 2B adenosine receptor antagonists","volume":"308","author":"Abo-Salem","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2020.104033_b0295","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1016\/j.ejmech.2011.05.023","article-title":"Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones","volume":"46","author":"Drabczy\u0144ska","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2018.00206","article-title":"Probing substituents in the 1- and 3-position: tetrahydropyrazino-annelated water-soluble xanthine derivatives as multi-target drugs with potent adenosine receptor antagonistic activity","volume":"6","author":"Koch","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0305","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1021\/jm400336x","article-title":"Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H\u20133,1-benzothiazin-4-ones","volume":"56","author":"St\u00f6\u00dfel","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0310","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1039\/C8MD00070K","article-title":"Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties","volume":"9","author":"Za\u0142uski","year":"2018","journal-title":"Medchemcomm."},{"key":"10.1016\/j.bioorg.2020.104033_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103071","article-title":"Structural modifications and in vitro pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H3 receptor ligands","volume":"91","author":"Szczepa\u0144ska","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104033_b0320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.brainres.2004.09.058","article-title":"Evaluation of the tail formalin test in mice as a new model to assess local analgesic effects","volume":"1029","author":"Kolesnikov","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.bioorg.2020.104033_b0325","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2020.104033_b0330","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-111-27849","article-title":"Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs","volume":"111","author":"Winter","year":"1962","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.bioorg.2020.104033_b0335","first-page":"237","article-title":"A new device for plethysmoscopic measuring of small objects","volume":"136","author":"Lence","year":"1962","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.bioorg.2020.104033_b0340","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0022-3565(25)12981-9","article-title":"Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics","volume":"125","author":"Hendershot","year":"1959","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2020.104033_b0345","unstructured":"Molecular Operating Environment (MOE), 2019.01; https:\/\/www.chemcomp.com\/ (last accessed 09.03.2020)."},{"key":"10.1016\/j.bioorg.2020.104033_b0350","unstructured":"Schr\u00f6dinger Release 2019-1: Schr\u00f6dinger, LLC, New York, NY, 2019."},{"key":"10.1016\/j.bioorg.2020.104033_b0355","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820313304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820313304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:12:04Z","timestamp":1758615124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820313304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":71,"alternative-id":["S0045206820313304"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104033","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"8-Benzylaminoxanthine scaffold variations for selective ligands acting on adenosine A2A receptors. Design, synthesis and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104033"}}